136866-27-8

Basic information

• Product Name: 3,5-Dichloropyrazine-2-carbaldehyde
• Synonyms: 3,5-dichloropyrazine-2-carbaldehyde;3,5-Dichloro-2-formylpyrazine;3,5-Dichloropyrazine-2-carboxaldehyde;3,5-Dichloro-2-formylpyrazine, 3,5-Dichloro-2-formyl-1,4-diazine
• CAS NO: 136866-27-8
• Molecular Formula: C5H2Cl2N2O
• Molecular Weight: 176.99
• Mol File: 136866-27-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 240.75 °C at 760 mmHg
• Flash Point: 99.403 °C
• Appearance: /
• Density: 1.588 g/cm³
• Vapor Pressure: 0.037mmHg at 25°C
• Refractive Index: 1.617
• PKA: -5.20±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dichloropyrazine-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloropyrazine-2-carbaldehyde(136866-27-8)
• EPA Substance Registry System: 3,5-Dichloropyrazine-2-carbaldehyde(136866-27-8)

Safety Data

• Hazardous Substances Data: 136866-27-8(Hazardous Substances Data)

Usage

Description

3,5-Dichloropyrazine-2-carbaldehyde is an organic compound characterized by its chemical structure that features a pyrazine core with two chlorine atoms at the 3rd and 5th positions and a formyl group (-CHO) at the 2nd position. 3,5-Dichloropyrazine-2-carbaldehyde is known for its potential applications in the synthesis of various pharmaceutical compounds and has garnered interest in the field of medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
3,5-Dichloropyrazine-2-carbaldehyde is used as an intermediate for the synthesis of substituted imidazolylmethyl pyridine and pyrazine derivatives. These derivatives are known as GABAA receptor ligands, which play a crucial role in the central nervous system by modulating the activity of the GABAA receptors. GABAA receptors are essential for regulating neuronal excitability and have been implicated in various neurological and psychiatric disorders. The development of ligands for these receptors can lead to the creation of novel therapeutic agents for conditions such as anxiety, epilepsy, and insomnia.

InChI:InChI=1/C5H2Cl2N2O/c6-4-1-8-3(2-10)5(7)9-4/h1-2H

Upstream product

• 330786-09-9 3,5-dichloro-pyrazine-2-carboxylic acid methyl ester 
• 312736-49-5 3,5-dichloropyrazine-2-carboxylic acid 
• 768-66-1 2,2,6,6-tetramethyl-piperidine 
• 4774-14-5 2,6-dichloropyrazine 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 1258393-93-9 2-(benzyl((3,5-dichloropyrazin-2-yl)methyl)amino)ethan-1-ol 
• 1258393-95-1 (2S)-1-{benzyl[(3,5-dichloropyrazin-2-yl)methyl]amino}propan-2-ol 
• 1426214-83-6 2-cyano-5-methyl-N-[4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide 
• 1935196-58-9 6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyrazine 
• 1255700-75-4 (R)-2-(3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenylamino)-6-phenyl-6,7-dihydropyrazino[2,3-f][1,4]oxazepin-8(9H)-yl)acetonitrile 
• 1255700-77-6 (R)-N-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-8-methyl-6-phenyl-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepin-3-amine 
• 1258393-94-0 8-benzyl-3-chloro-6,7,8,9-tetrahydropyrazino[2,3-f][1,4]oxazepine 

Relevant articles and documents

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME

The disclosure is in part directed to crystalline forms of (R)-1′-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4′-piperidin]-3-amine, its salt, and variants thereof.

PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.

Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands

Substituted imidazolylmethyl pyridine and pyrazine derivatives that bind to GABAA receptors are provided. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).